Related Experiment Video
Updated: Feb 27, 2026
06:28
Author Spotlight: Asymmetric Field Flow Fractionation for Bioreactor Integration
Published on: February 2, 2024
1.5K
Evaluation of a New Technique for iFOBT Utilising a New Sample Collection Device with Increased Buffer Stability
Markus Bruns-Toepler1, Philip Hardt2
1Department of Gastroenterology, Medical Clinic II, Justus Liebig University of Giessen, Giessen, Germany markus.bruns-toepler@innere.med.uni-giessen.de.
Anticancer Research
|July 3, 2017
Summary
The Hb Smart enzyme-linked immunosorbent assay (ELISA) shows high specificity (98%) for colorectal cancer (CRC) screening. This assay is stable and suitable for large-scale fecal hemoglobin analysis.
Area of Science:
- Biochemistry
- Oncology
- Medical Diagnostics
Background:
- Colorectal cancer (CRC) screening is crucial for early detection and improved patient outcomes.
- Accurate and stable methods for fecal hemoglobin detection are needed for effective screening programs.
Purpose of the Study:
- To evaluate the specificity and sensitivity of the Hb Smart enzyme-linked immunosorbent assay (ELISA) for CRC detection compared to colonoscopy.
- To assess the stability of a novel sample collection device with a specialized buffer for hemoglobin extraction from stool samples.
Main Methods:
- Stool samples were analyzed using the Hb Smart ELISA method.
- Hemoglobin stability was determined daily over 5 days at 4°C and room temperature in both extraction buffer and native stool samples.
Main Results:
- The Hb Smart ELISA demonstrated a sensitivity of 78.4% and a specificity of 98% for CRC detection.
- Hemoglobin remained stable in the extraction buffer and stool samples throughout the 5-day storage period under both tested conditions.
Conclusions:
- The Hb Smart assay is a promising tool for large-scale CRC screening due to its high specificity, sample handling ease, and demonstrated stability.
- The novel sample collection device and buffer ensure reliable hemoglobin analysis in fecal samples.
